Type I interferons (IFNs), ribavirin, lopinavir/ritonavir, chloroquine/hydroxychloroquine, and remdesivir emerge as the primary options for in-hospital treatment of patients with COVID-19, focused on reducing the viral load. Although more experimental and clinical evidence is required, the accumulated in vitro and clinical knowledge discussed here supports those drugs as feasible alternatives to face the SARS-CoV infection in the short term, whereas more effective measures arise from the world scientific community.
After 18 years since the first SARS outbreak, the studies in potential antiviral therapies for SARS-CoV and MERS-CoV have not progressed as fast as needed. This is reflected in the current uncertainties evidenced by the health personnel in the management of severe patients infected with the novel SARSCoV-2. Although several potential drugs have been tested in vitro and in vivo for treating infections with SARS coronaviruses, the clinical evidence is still limited, and as a consequence, there is no proven antiviral therapy for any SARS disease. There is comparatively more evidence regarding the use of type I IFNs, ribavirin, and lopinavir/ritonavir for the treatment of SARS diseases, showing some benefits, but their application in late stages of infection is ineffective. Chloroquine, hydroxychloroquine, and remdesivir are the most promising alternatives for treating severe patients, even after several days of infection, but the associated clinical evidence is still minimal. Furthermore, from this group, the only licensed drugs are chloroquine and hydroxychloroquine, and therefore, they are readily available and cheap enough to be accessible for all healthcare personnel around the world.
Reference & Source information: https://japsonline.com/
Read more on: